Cellomics Inc. and University of California, San Francisco Comprehensive Cancer Center to Collabora
Pittsburgh, PA – July 8, 2002 - Cellomics, Inc. announced today that they have signed a collaborative agreement with the University of California, San Francisco (UCSF) Comprehensive Cancer Center. UCSF will implement Cellomics’ High Content Screening (HCS) technology to enable the Cancer Center to further advance its cancer biology research capabilities. One of the world’s leading academic cancer research institutions, the UCSF Comprehensive Cancer Center will use Cellomics ArrayScan® HCS Reader, KineticScan™ HCS Reader, vHCS™ Discovery Toolbox and Cellomics proprietary applications in their extensive research.
“We are extremely pleased the Comprehensive Cancer Center have chosen to implement Cellomics’ HCS technologies in their cancer biology research,” stated D. Lansing Taylor, CEO of Cellomics. “We are excited to be working with Dr. Joe Gray, one of the world’s leading cancer scientists with great expertise in cytometry. In addition, we are confident the resulting data will enable the Cancer Center to enhance its development of novel assays to be used in their cancer research programs.” Cellomics, Inc. is pioneering the field of cellular knowledge extraction. Its unique technology, referred to as High Content Screening, integrates fluorescent reagents, kits, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetics systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences. This automated platform, when applied to lead optimization, predictive toxicology, and new target validation, is proving to reduce the “idea-to-discovery” cycle time in drug discovery while increasing the probability of the therapeutic success of leads as well as reducing the cycle time in research and similar institutions. Currently, Cellomics’ proprietary ArrayScan and KineticScan HCS Readers, along with its’ vHCS Discovery Toolbox software and proprietary applications, are in use at multiple sites within the top fifteen pharmaceutical companies in the world, as well as several additional leading pharmaceutical and biotechnology companies, and academic centers. Housed within one of the nation's top biomedical research universities, the UCSF Comprehensive Cancer Center brings together hundreds of researchers and clinicians dedicated to four fundamental pursuits: basic science research into the causes and events of cancer progression; clinical research to translate new knowledge into viable treatments; sensitive, state-of-the-art patient care; and programs in epidemiology, prevention, and cancer control. Basic scientists and clinical health care providers work together toward the translation of promising ideas into the creation of new and better treatments for cancer patients everywhere.
For further information, contact:
Judy P. Masucci, PhD Director, Marketing Cellomics, Inc. 100 Technology Drive Pittsburgh, PA 15219 412.770.2353 412.770.2450 (fax)
Last Updated ( Monday, 21 June 2004 )
Upcoming Events
December 13, 2008 ASCB 2008 Please visit our booth at the 49th Annual Meeting of the American Society for Cell Biology ...
Home 
Cellomics Inc. and University of California, San Francisco Comprehensive Cancer Center to Collabora
top